Last reviewed · How we verify
PharmaEssentia Japan K.K. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| P1101 | P1101 | phase 3 | Thrombopoietin receptor agonist | TPO receptor (c-Mpl) | Hematology |
Therapeutic area mix
- Hematology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Amgen · 1 shared drug class
- Centro de Atencion e Investigacion Medica · 1 shared drug class
- Eisai Inc. · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Hvidovre University Hospital · 1 shared drug class
- Institute of Hematology & Blood Diseases Hospital, China · 1 shared drug class
- Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
- Kyowa Kirin Korea Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for PharmaEssentia Japan K.K.:
- PharmaEssentia Japan K.K. pipeline updates — RSS
- PharmaEssentia Japan K.K. pipeline updates — Atom
- PharmaEssentia Japan K.K. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). PharmaEssentia Japan K.K. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pharmaessentia-japan-k-k. Accessed 2026-05-16.